Get the Stockscreener App
1.04
48.00%
-0.96
After Hours:
1.02
-0.02
-1.92%
Galectin Therapeutics Inc stock is traded at $1.04, with a volume of 9.23M.
It is down -48.00% in the last 24 hours and down -63.06% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$2.00
Open:
$1.18
24h Volume:
9.23M
Relative Volume:
21.86
Market Cap:
$65.27M
Revenue:
-
Net Income/Loss:
$-41.07M
P/E Ratio:
-1.5758
EPS:
-0.66
Net Cash Flow:
$-32.97M
1W Performance:
-50.71%
1M Performance:
-63.06%
6M Performance:
-57.02%
1Y Performance:
-39.18%
1-Day Range:
$0.726
$1.50
1-Week Range:
$0.726
$2.36
52-Week Range:
$0.726
$4.2684
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
1.04 | 65.27M | 0 | -41.07M | -32.97M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Belapectin shows promise in liver disease trial - Investing.com India
Dow Surges Over 600 Points, Gold Jumps 1.5% - Benzinga
Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint - MarketWatch
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher - Benzinga
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Galectin Therapeutics stock hits 52-week low at $1.23 - Investing.com
Phase III MASH Miss Sends Galectin Stock Tumbling - BioSpace
Dow Surges 100 Points, Carnival Earnings Top Views - Benzinga
Belapectin shows promise in liver disease trial By Investing.com - Investing.com South Africa
Galectin stock drops after MASH trial data (GALT:NASDAQ) - Seeking Alpha
Galectin's Belapectin Shows 48.9% Reduction in MASH Cirrhosis Trial, Mixed Endpoint Results - StockTitan
Gilead and Terray Therapeutics collaborate on drug discovery - BioWorld Online
The Pharma Bro Martin Shkreli Wants You To Short Bitcoin, MicroStrategy, And Quantum Computing Stocks - Wccftech
Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT) - Defense World
Non-Alcoholic Steatohepatitis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight - EIN News
Stock Traders Buy High Volume of Put Options on Galectin Therapeutics (NASDAQ:GALT) - MarketBeat
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Short Mafia Attacking Galectin Therapeutics (NASDAQ : GALT) Ahead of Planned Year-End Readout - Insider Financial
Liver Cirrhosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports - EIN News
Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks - Yahoo Finance
Ensysce Biosciences (NASDAQ:ENSC) Stock Quotes, Forecast and News Summary - Benzinga
Full Stock Market News from 2024-12-06 - StockTitan
GALT (Galectin Therapeutics) E10 : $-0.72 (As of Sep. 2024) - GuruFocus.com
Psoriasis Pipeline Therapeutics Assessment Report 2024 (Updated) - openPR
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
Bank of America Corp (BAC-N) QuotePress Release - The Globe and Mail
StockNews.com Upgrades Galectin Therapeutics (NASDAQ:GALT) to "Hold" - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.com - Defense World
Non-alcoholic Steatohepatitis Treatment Market Projected to Show Strong Growth - openPR
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - The Manila Times
Galectin Therapeutics Advances NAVIGATE Trial for MASH Cirrhosis Treatment, December Readout on Track | GALT Stock News - StockTitan
HC Wainwright Analysts Decrease Earnings Estimates for GALT - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Earns Buy Rating from HC Wainwright - MarketBeat
Galectin Therapeutics Reports Increased Q3 Losses - TipRanks
Galectin Therapeutics Inc (GALT) Quarterly 10-Q Report - Quartzy
Galectin Therapeutics Advances Galectin-Based Therapeutics Pipeline - TipRanks
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update - The Manila Times
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21 - The Manila Times
Galectin Q3 Loss Narrows to $11.2M; Key NAVIGATE Trial Results Due December | GALT Stock News - StockTitan
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight - The Malaysian Reserve
Galectin Therapeutics (NASDAQ: GALT): Disrupting Merck’s Cancer Dominance - Insider Financial
Individual investors who hold 54% of Galectin Therapeutics Inc. (NASDAQ:GALT) gained 12%, insiders profited as well - Simply Wall St
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart
Non-Alcoholic Steatohepatitis Market to Show Remarkable - openPR
Psoriasis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Recent Developments | Astrazeneca, Bayer, Sanofi, Pfizer, Merck, Novartis - Barchart
Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, - openPR
LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR
Galectin therapeutics director Eldred Kary buys $1,300 in stock By Investing.com - Investing.com South Africa
Galectin therapeutics director Eldred Kary buys $1,300 in stock - Investing.com
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FREEMAN KEVIN D | Director |
Oct 17 '24 |
Buy |
2.64 |
1,300 |
3,432 |
34,769 |
| FREEMAN KEVIN D | Director |
Oct 16 '24 |
Buy |
2.70 |
5,000 |
13,500 |
80,000 |
| FREEMAN KEVIN D | Director |
Oct 16 '24 |
Buy |
2.70 |
5,000 |
13,500 |
33,469 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):